GlassScriptPhysician profile
Vishal Sharma
NPI 1851494769
$5,997.80
in general payments reported to CMS, 2019-2025
35 companies · $1,872 in 2025
The $1,872 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $367 · 2021: $490 · 2022: $835 · 2023: $1,186 · 2024: $1,041 · 2025: $1,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,204.05 | 2019-2025 | Unity, Ngenuity, Hydrus Microstent |
| Pentax of America, INC. | $581.42 | 2021-2025 | Pentax Medical, Inspira, C2 Cryoballoon |
| Abbvie INC. | $288.09 | 2022-2024 | Qulipta, Ubrelvy, Vraylar |
| Fujifilm Healthcare Americas Corporation | $214.40 | 2023 | Fujifilm |
| Amgen INC. | $182.83 | 2020-2025 | Repatha, Otezla, Tepezza |
| Glaukos Corporation | $181.81 | 2025 | Istent, Idosetr |
| Janssen Pharmaceuticals, INC | $162.66 | 2020-2022 | |
| Novo Nordisk INC | $160.13 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $153.48 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $101.49 | 2020-2025 | Jardiance |
| Bausch & Lomb Americas INC. | $84.61 | 2024-2025 | Scoutpro Osmolarity System, Xiidra, Miebo |
| Rayner Intraocular Lenses Limited | $58.43 | 2025 | Omidria |
| Johnson & Johnson Surgical Vision, INC. | $55.62 | 2019-2024 | Tecnis Iol |
| Dexcom, INC. | $53.18 | 2023-2024 | Dexcom G6 Transmitter |
| Oyster Point Pharma, INC. | $44.13 | 2024 | Tyrvaya |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $42.55 | 2023 | Quviviq |
| Sight Sciences, INC. | $40.85 | 2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $37.29 | 2023 | Cequa |
| Horizon Therapeutics Plc | $34.79 | 2023 | Tepezza |
| Biotissue Holdings INC. | $30.43 | 2024 | |
| Travere Therapeutics, INC. | $27.34 | 2021 | |
| Pfizer INC. | $26.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $25.36 | 2020-2022 | |
| Shire North American Group INC | $22.87 | 2019 | |
| Eisai INC. | $20.24 | 2021 | |
| Amarin Pharma, INC. | $19.62 | 2022 | |
| Shield Therapeutics INC | $19.47 | 2023 | Accrufer |
| Rxsight INC | $19.26 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $19.11 | 2024 | Iheezo |
| Daiichi Sankyo INC. | $15.65 | 2023 | Injectafer |
| Corcept Therapeutics | $15.52 | 2025 | Korlym |
| Ibsa Pharma INC. | $14.30 | 2024 | Tirosint, Licart |
| Sanofi Pasteur INC. | $14.11 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.36 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.